BioSpace News Archive

Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today that it has received clearance from the U.S. Food & Drug Administration (FDA) to market the ProLift micro Expandable Spacer System.

Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited iNK and CAR -iNK cells derived from induced pluripotent stem cells and Flex-NK™ cell engager multifunctional antibodies, announced that Evelyn D’An has been appointed as Chief Financial Officer.

A quick stick in the arm with an approved COVID-19 vaccine elicits a flurry of activity in the body’s immune system.

SOPHiA GENETICS SA, the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced the launch of SOPHiA Clinical Exome Solution v3, a new genomic application that offers enhanced probe design and increased detection capabilities for a deeper investigation of Mendelian diseases.

Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced that Mark McKenna, Chairman and Chief Executive Officer and Allison Luo, M.D., Chief Medical Officer, will participate in a fireside chat at the Jefferies Virtual Next Generation IBD Therapeutics Summit on Tuesday, October 19, 2021 at 11:30 a.m. ET.

Homology Medicines, Inc., a genetic medicines company, announced the pheEDIT Phase 1 clinical trial for HMI-103, a one-time, in vivo product candidate that utilizes a gene editing approach for phenylketonuria, based on the Investigational New Drug Application clearance from the U.S. Food and Drug Administration.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced preliminary financial results for its third quarter ended September 30, 2021.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced the prioritization of its promising, next-generation candidate, RGLS8429, for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on October 26, 2021, at 3:00 p.m. ET it will host a key opinion leader (KOL) webinar on ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with various complement mediated diseases.

Adicet Bio, Inc., a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, announced Blake Aftab, Ph.D., has been promoted to the position of Senior Vice President and Chief Scientific Officer.